Since 2021, Chinese authorities have approved 113 domestically developed innovative drugs, propelling the pharmaceutical market to a scale of 100 billion yuan (approximately 13.89 billion U.S. dollars).
This milestone was highlighted at the ongoing China Pharmaceutical Industry Development Conference in Shanghai on Saturday.
The medical device sector has also made remarkable progress. During the 14th Five-Year Plan period (2021-2025), 165 innovative devices received approval, many integrating advanced technologies such as deep learning, magnetic levitation, and magnetic resonance monitoring.
The report presented at the conference emphasizes strides in biological drug industrialization, intelligent manufacturing, and the green development of active pharmaceutical ingredients, showcasing China’s commitment to sustainable and cutting-edge pharmaceutical advancements.
The conference, which began on Saturday, will continue until November 18, gathering industry leaders to discuss the future of China’s pharmaceutical innovation and development.
